A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety.
Mara MantieroMarta BiniMaggie PolignanoLuca PorcuRoberta SanfilippoChiara FabbroniGabriella ParmaMariateresa LapresaCarmelo CalidonaCecilia SilvestriAndrea FranzaFrancesco RaspagliesiNicoletta ColomboMonika DucceschiPublished in: Cancers (2023)
Pazopanib in everyday clinical practice is safe and shows a good disease control rate with prolonged survival.